To view this email as a web page, click here.
 
It may be time to update the melanoma staging system, researchers report
A new study calls into question the accuracy of a staging system used in melanoma, reserchers reported at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO) on June 4.
ADVERTISEMENT
 
Immunotherapy still works post treatment in melanoma
Pembrolizumab has antitumor activity that is durable long after treatment is stopped in patients with advanced melanoma, researchers reported at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO) on June 4.
ADVERTISEMENT
 
Combination therapy improves survival in melanoma
The combination of encorafenib plus binimetinib significantly improved overall survival versus vemurafenib in patients with BRAF-mutant melanoma, updated results of the randomized, phase 3 COLUMBUS trial show.
ADVERTISEMENT
 
JOB OPPORTUNITIES
 
AZ - Integrated Dermatology
CO - Leavitt Management Group
CO - Leavitt Management Group
CT - Integrated Dermatology
CT - Integrated Dermatology
CT - Integrated Dermatology
CT - Integrated Dermatology
FL - Integrated Dermatology
FL - Integrated Dermatology
FL - Leavitt Management Group
FL - Leavitt Management Group
FL - Leavitt Management Group
FL - Leavitt Management Group
GA - Leavitt Management Group
IL - Integrated Dermatology
MA - Integrated Dermatology
MA - Integrated Dermatology
MA - Integrated Dermatology
MD - Integrated Dermatology
MD - Integrated Dermatology
MD - Integrated Dermatology
MI - Leavitt Management Group
MI - Leavitt Management Group
National - Integrated Dermatology
NC - Integrated Dermatology
NJ - Integrated Dermatology
OR - Cynthia Dreyer MD
PA - Leavitt Management Group
PA - Integrated Dermatology
PA - Milton S Hershey Medical Center
RI - Leavitt Management Group
TN - Integrated Dermatology
TX - Company Confidential
VA - Integrated Dermatology
WY - Leavitt Management Group
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.